Our Experts

The whitepaper lays out a practical “medical affairs blueprint” for pre-revenue and early-commercial biotechs (and biotechs entering new markets without medical infrastructure) to build medical affairs from a blank slate, treating it as a core strategic pillar from the outset rather than a late-stage support function. It argues that, in a biotech context where the company’s survival often hinges on a single asset, delaying medical affairs is not just outdated but a material strategic liability. Instead, early medical affairs should act as a catalytic, integrative force that elevates value across approval, access, advocacy, and adoption from day one.